{"id":"W2321989483","doi":"10.17925/ee.2016.12.01.31","title":"Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy","year":2016,"lang":"en","type":"editorial","venue":"touchREVIEWS in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Novo Nordisk; Sanofi; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Empagliflozin; Medicine; Type 2 diabetes; Clinical endpoint; Diabetes mellitus; Incidence (geometry); Endpoint Determination; Internal medicine; Pharmacology; Clinical trial; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002917859,0.0007188044,0.003071166,0.0003740271,0.00004495927,0.00002142322,0.0003508599,0.000406848,0.0001615262],"category_scores_gemma":[0.0005105793,0.0004072655,0.0007969307,0.0002137353,0.0001407437,0.00007039795,0.0001082199,0.0003966564,0.0001857941],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002409978,"about_ca_system_score_gemma":0.0002190277,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004298065,"about_ca_topic_score_gemma":0.00008249728,"domain_scores_codex":[0.9967405,0.0001549115,0.0006689031,0.0009089852,0.0004968932,0.001029778],"domain_scores_gemma":[0.9973459,0.0006518839,0.0002354337,0.001422538,0.0002305728,0.00011371],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00019748,0.0001871799,0.006545165,0.0006424351,0.003654271,0.00008257249,0.00001642237,5.551009e-7,0.00000437681,0.00008595712,0.7235117,0.2650719],"study_design_scores_gemma":[0.00769679,0.001713216,0.0006679998,0.0006724327,0.001350237,0.000001862703,0.000007347578,3.524993e-7,0.00006756779,0.0001051006,0.9872909,0.0004262399],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.003418991,0.2672639,0.00005194185,0.001691922,0.7119772,0.008839238,0.0001266286,0.0002612332,0.006368956],"genre_scores_gemma":[0.0004901532,0.3985901,0.002731901,0.001303942,0.5681852,0.00597781,0.001436748,0.0004130247,0.02087104],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.2646457,"threshold_uncertainty_score":0.9998379,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03218821642641539,"score_gpt":0.3249771707485819,"score_spread":0.2927889543221665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}